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Abstract: Stroke remains a leading cause of disability.
Most patients show some degree of spontaneous recovery, but
this is generally incomplete. Studies on the neurobiology of
this recovery are providing clues to therapeutic interventions
that aim to improve patient outcomes. A number of potential
such restorative therapies are reviewed. Numerous treatment
strategies are under study. Most have a time window meas-
ured in days or weeks and so have the potential to help a
large fraction of patients. This review considers these thera-
pies, as well as points to consider in translating their applica-
tion to human trials. VC 2011 Wiley Periodicals, Inc. Head Neck
33: S5–S7, 2011
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Brain repair can be deﬁned as a process—spontaneous
or therapeutically induced—that restores some aspect
of brain structure or function after an insult. Repair
contrasts with other therapeutic strategies in cerebro-
vascular disease such as prevention or approaches that
aim to limit the injury such as neuroprotection or reper-
fusion. Instead, repair is focused on regrowth, repair,
restoration, rewiring, and rehabilitation.
The burden of disability after stroke is large. An
estimated 6,400,000 American adults have had a symp-
tomatic stroke, with a prevalence that increases with
age. Note too that an estimated 13 million people in the
United States have had a silent stroke. Each year,
795,000 people experience a stroke, 610,000 of which
are ﬁrst-ever symptomatic stroke. The mean survival
after stroke is 8 years, with approximately 85% of
patients living past the ﬁrst year of stroke.1
Current therapies for a new stroke reduce disability
in a limited fraction of patients. The only drug approved
to treat acute stroke is tissue plasminogen activator.2,3
A limited fraction of patients receive this medicine,4 in
large part because of the narrow time window for safe
drug administration. Despite recent data supporting
administration of intravenous tissue plasminogen
activator up to 4.5 hours after ischemic stroke onset, it
continues to be true that only a minority of patients
with acute stroke receive this drug. Moreover, of those
so treated, half or more have signiﬁcant long-term dis-
ability.2,3 Because most repair-based approaches have a
time window measured in days rather than hours, any
repair-based approach that achieves regulatory ap-
proval will likely have the potential to help a large pro-
portion of patients affected by stroke.
Preclinical studies have characterized the neurobi-
ology of spontaneous stroke recovery. After an experi-
mental infarct, brain regions become excitable, in some
cases showing gamma-Aminobutyric acid (GABA) re-
ceptor downregulation and increased N-Methyl-D-as-
partic acid (NMDA) receptor binding. Expression
changes for a number of genes, for example, resulting
in increased levels of several growth factors. Angiogen-
esis is accompanied by structural changes in axons,
dendrites, and synapses. These changes are often pref-
erentially seen in the area surrounding an infarct and
in areas with network connections to injured zones.
Functional neuroimaging studies in humans in general
are concordant, showing changes in network activity
and reorganization in attempts to compensate. For
example, increased activity is often seen in unaffected
nodes of an injured brain network, behaviors that are
normally highly lateralized can become more bilaterally
organized, and cortical representational maps shift.5–10
Treating stroke recovery is a 4-dimensional issue.
Thus an important consideration is that the cellular
and biochemical underpinnings of recovery, many of
which are potential therapeutic targets, evolve over
time.9,11,12 Targets that help the brain 1 week can be
deleterious the next. For example, long-term effects of a
GABA agonist or NMDA receptor blocker can be favor-
able if administered in the early hours after stroke13,14
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but deleterious if initiated days later,15–17 and the
reverse may be true for matrix metalloproteinases.18
A number of categories of therapy are being exam-
ined in relation to promoting brain repair.19 Many
have reached the step of human study, although gen-
erally in earlier-phase trials. These therapies include
growth factors, with most studies to date having a
particular focus on hematopoetic growth factors.
Other large molecules are also under study, such as
monoclonal antibodies to block speciﬁc biochemical
events. Numerous small molecules have been exam-
ined, such as amphetamine, inosine, levodopa, ropi-
nirole, escitalopram, sildenaﬁl, and niacin. Many of
these target speciﬁc neurotransmitter systems. Cell-
based therapies are receiving increased attention,
with numerous types under consideration. Some
therapies target endogenous neural stem cells,
whereas others administer various exogenous cells
including xenografts, transformed tumor cells, adult
stem cells such as marrow stromal cells, stem cells
with modiﬁed genes or a bioscaffold, umbilical cord
cells, placental cells, fetal stem cells, and embryonic
stem cells. Various intensive therapy regimens, such
as constraint-induced therapy, are being examined,
particularly for motor and language retraining. A
range of robotic devices is under study. In some cases
these act as an extension of the approach to provide
intensive therapy, and in other cases these offer spe-
ciﬁc advantages such as the potential to provide tele-
medicine or increase use via virtual games. Brain
stimulation is also being studied, including transcra-
nial magnetic stimulation, epidural cortical stimula-
tion, transcranial direct current stimulation, and use
of laser devices. There is precedence for this, because
the gold standard therapy for major depression
remains a form of brain stimulation, electroconvulsive
therapy. Also, with respect to the enormous cognitive
potential of the human brain and building on effective
interventions in healthy subjects, strategies that
emphasize imagery and observation are being stud-
ied, particularly for the motor system.
The effectiveness of restorative therapies can be
maximized with attention to certain issues.20 First,
brain repair is time sensitive. Some biologic targets are
only relevant during a speciﬁc time period after stroke.
Furthermore, as above, some therapies can have differ-
ent effects on stroke depending on timing. Second,
brain repair is also experience dependent. Since the
classic study by Feeney et al,21 which showed that a
stimulant promoted improved motor outcome only
when its exposure was paired with training, increasing
evidence suggests that a restorative therapy needs the
right kind of experience to produce the best results.
Third, patient stratiﬁcation is likely important to stud-
ies of poststroke brain repair. Numerous variables have
been found to be potential predictors of stroke outcome,
including location and size of injury,22,23 genotype,24
measures of brain function,25 and degree of depres-
sion.26,27 Such measures may be of pivotal value in deﬁ-
nining the population most likely to beneﬁt from a
given therapy. Fourth, domain-speciﬁc measures might
be useful to measure treatment effects.28 Improvement
in global clinical status is of course a goal of paramount
importance, but a treatment that provides gains by pro-
moting neuroplasticity might demonstrate maximum
effect in brain networks that have subtotal injury. A
behavior whose underlying brain regions are destroyed
is less likely to improve than a behavior whose underly-
ing regions are accessible to a restorative therapy. Thus
a domain whose neural underpinnings are partially
spared, such as arm motor function or language, might
show substantial gains in response to a restorative
therapy, with only modest effects on global measures of
poststroke outcome, and this might be considered
worthwhile by many patients and so worthy of meas-
uring in clinical trials.
An additional principle that is of particular rele-
vance to head, neck, and aerodigestive tract functions
is that the nature of brain organization before stroke
inﬂuences poststroke brain plasticity. For example, in
healthy subjects, some behaviors such as language or
hand movement tend to be highly lateralized (ie, gener-
ation of the behavior involves mainly one hemisphere),
and other behaviors such as bulbar and facial move-
ment tend to be less lateralized (ie, generation of the
behavior involves both hemispheres). These differences
remain apparent after stroke. Cramer and Crafton29
found that face movement is more bilaterally organized
than is shoulder or arm movement in healthy subjects
(ie, before any stroke), and that this remained true af-
ter stroke. Such a difference could have functional
implications. Hamdy et al30 found that the cortical rep-
resentation for swallowing is normally present in both
hemipsheres. Not surprisingly therefore patients with
dysphagia who recovered after stroke showed an
increase in their cortical pharyngeal map size within
the unaffected hemisphere, whereas patients who con-
tinued to have dysphagia did not show this change.31
For reorganization of brain maps after stroke, the pat-
tern of brain reorganization can inﬂuence behavioral
status, and this pattern is at times constrained by fea-
tures of normal brain organization.
Stroke remains a major source of disability. An
emerging class of therapeutics focused on repair is
under study. When applied according to selected neuro-
biologic principles, these therapies have the potential
to improve outcome for many patients after stroke.
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